Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jared Weiss is an Associate Professor of Clinical Research for Hematology/Oncology at the University of North Carolina School of Medicine in Chapel Hill, NC. He completed fellowship in Hematology and Oncology at the University of Pennsylvania and residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, MA. He received his Doctor of Medicine at Yale University School of Medicine in New Haven, CT and his B.S. in neuroscience at Brown University, in Providence, RI.

GRACE Targeted Therapies in Lung Cancer 2021 - The Complimentary Use of Liquid and Tissue Biopsies
GRACE Targeted Therapies in Lung Cancer 2021 - The Complimentary Use of Liquid and Tissue Biopsies
Author
Jared Weiss, MD
Image
Targeted Therapies Patient Forum 2021
The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time.

For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty.  For a first glance at the full playlist of videos, visit the event on our YouTube channel. 

YOUTUBE PLAYLIST

 

In this video, the AM panel of oncologists, with Drs. Weiss, Dagogo-Jack, and Thompson discuss the complimentary use of liquid and tissue biopsies.

A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech

Image

AstraZeneca, Novartis, Lilly, Blueprint Medicines, Takeda Oncology, Boehringer Ingelheim, Genentech

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora